"In twelve months this should see a share price at approximately $50. A takeover at that time, with risks reduced and future potential identifiable then a healthy premium takeover towards $150 is not unreasonable."
Given that Neuren, post FDA approval, is now trading at a price around the same as after successful phase 2 results, why would a buyer pay a 300% premium?
Ann: 2023 Annual Report to shareholders, page-143
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.50 |
Change
0.190(0.98%) |
Mkt cap ! $2.490B | |||
| Open | High | Low | Value | Volume |
| $19.39 | $19.98 | $19.38 | $7.285M | 370.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 7318 | $19.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.52 | 593 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.55 |
Change
0.190 ( 0.83 %) |
||||
| Open | High | Low | Volume | ||
| $19.41 | $19.97 | $19.39 | 83274 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| NEU (ASX) Chart |